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Abstract 
Protein Kinase R (PKR) is a key component of the innate immune antiviral 
response.  PKR is activated upon binding to dsRNA. However, recent studies have 
shown that PKR can also bind to and become activated by duplex RNAs containing 
complex secondary structure. The mechanism of PKR binding and activation by these 
RNAs is currently not known. The approach taken here to determine the mechanism of 
PKR binding by these RNAs is through the development of PKR constructs that are 
capable of covalently binding to RNAs. Constructs were created by site-specific 
incorporation of an unnatural, photoactivatable amino acid within PKR. These 
constructs were incubated with RNA and crosslinked at various UV light wavelengths. 
Subsequently, SDS-PAGE was performed to detect crosslinking products. The incentive 
for developing these crosslinking constructs is to use them to map PKR binding on 
RNAs and to determine the correlation between RNA structural features and PKR 
activation or inhibition. 
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Introduction 
 Protein Kinase R (PKR) is an enzyme involved in a multitude of cellular 
processes.  Some of these critical processes are responses to stress signals such as 
cytokine responses, apoptosis, cell-growth, and pathogenic invasion (1-4). Although 
PKR is involved in a plethora of intracellular signaling pathways, we focus here on its 
role in the innate immune response.  
 
Role of PKR in the Innate Immune Response 
The innate immunity pathway is a non-adaptive defense mechanism that is 
activated by several pathogen-associated molecules. It is the initial response made by 
the body to eliminate pathogens and prevent disease (5). One protein involved in the 
human innate immune response is PKR. PKR is a cytoplasmic kinase that is induced by 
interferon as a response to pathogenic invasion (Figure 1) (6). PKR is composed of 551 
amino acids and contains a C-terminal kinase domain connected to its N-terminal 
dsRNA-binding domain (dsRBD) by a 90 amino acid flexible linker (Figure 2). The 
protein becomes activated upon binding to dsRNA, a typical byproduct of viral 
replication (7). PKR binding to dsRNA occurs via its dsRBD, leading to activation of the 
kinase domain by autophosphorylation (8). Activated PKR then goes on to 
phosphorylate cellular substrates such as the alpha subunit of eukaryotic initiation 
factor (eIF2α), a protein involved in the initiation phase of translation (9). eIF2α’s role 
is to mediate the binding of the initiator tRNA to the ribosome in a GTP-dependent 
manner; phosphorylation of eIF2α reduces protein synthesis by inhibiting initiation 
(10). Activation of PKR is crucial in that it inhibits translation and consequently, the 
replication of pathogens in infected cells.  
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PKR Structure  
The critical structural domains of PKR are the catalytic kinase domain and the 
dsRBD. Upon activation, the kinase domain of PKR is autophosphorylated at multiple 
residues, including threonine 446 located in a flexible loop called the activation loop.  
Activated PKR than goes on to phosphorylate serine and threonine residues on 
substrates (11). 
The other critical domain of PKR is the N-terminal dsRBD, which consists of two 
dsRNA-binding motifs, double-stranded RNA Binding Motif 1 (dsRBM1) and double-
stranded RNA Binding Motif 2 (dsRBM2) (12). The dsRBD of PKR is among one of the 
many dsRBDs found in a multitude of proteins across various taxa (13). The dsRBD is a 
highly conserved structure that is typically 65-70 amino acids long (14). It contains a 
conserved α-β-β-β-α topology, in which the N- and C- terminal α-helices pack against 
one face of a three-stranded antiparallel β-sheet (15). The domain is present in proteins 
implicated in many aspects of cellular life, from RNA editing, RNA processing, RNA 
transport, RNA silencing, and antiviral response as is the case with PKR.   
The successful activation of PKR is attributed to the binding of the protein’s 
dsRBD to dsRNA in a sequence independent manner (16). In addition, the dsRBD is 
highly specific for dsRNA with little or no observable binding to ssRNA, dsDNA, or 
ssDNA; the size and shape of the grooves confers specificity for dsRNA over dsDNA (17). 
The sequence independent characteristic of the dsRBD is due to the limited interaction 
with the bases on dsRNA (18). Structural studies of dsRBDs indicate that protein-RNA 
contacts are mediated through aromatic and basic residues, mostly located throughout 
looped regions within the domain (19-20). Mutational analyses of various different 
dsRBDs have demonstrated the importance of the highly conserved α-helix at the C-
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terminal end of the domain for the interaction with RNA.  The basic amino acids within 
this α-helical region contact the RNA (21). 
 
PKR Activation Model 
PKR is potently activated by dsRNAs upon binding via the dsRBD. The most well 
accepted structural model for PKR activation suggests that PKR exists in an open 
conformation whereby dimerization of PKR is necessary for autophosphorylation and 
activation (Figure 3) (22). This model is supported by the observation that dimerization 
of PKR can initiate autophosphorylation reactions in the absence of dsRNA (23).  
Inactive PKR exists primarily as a monomer but can dimerize weakly, with a 
dissociation constant of 500 µM. In the presence of dsRNA, autophosphorylation rates 
are greatly increased and the population of PKR dimers is enhanced because it is 
thought that dsRNA serves as a scaffold for PKR dimerization. Therefore, in the 
presence of dsRNA, the population of PKR molecules forming dimers is increased 
resulting in greater autophosphorylation activity. A characteristic feature of PKR 
autophosphorylation is the bell shaped curve of activation where small concentrations of 
dsRNA activate but higher concentrations inhibit the protein (24). The current 
interpretation is that low concentrations of dsRNAs favor the assembly of PKR dimers 
on a single dsRNA whereas high concentrations of dsRNA cause PKR monomers to 
separate onto different molecules of dsRNA (25-26). 
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Interaction of PKR with RNA 
 In vitro activation studies have revealed that a dsRNA of 85bp is the optimal 
length for PKR activation and that a dsRNA of 30bp is the minimum length requirement 
for binding and activation (27). A minimum dsRNA length requirement suggests that 
the RNA must be long enough to accommodate two PKR monomers. PKR interactions 
with RNAs in the cell are not limited to perfect duplexes. Some of these RNAs contain 
complex secondary structures such as stem-loops and bulges, with single- and double-
stranded regions. It is believed that the secondary structures of various RNAs that 
interact with PKR determine the RNA’s ability to induce either PKR activation or 
inhibition. As an example, one study showed PKR activation to be induced by a 16 bp 
stem loop RNA containing  ~10 nucleotide ssRNA tails at the 5’ and 3’ ends (ss-dsRNA) 
(28). Most notable about this RNA activator is that its structure deviates substantially 
from the typical structural requirements needed to activate PKR. Although the dsRNA 
stem loop of the 16 bp ss-dsRNA contains less than the minimal length (30 bp) required 
to activate PKR, the ss-dsRNA still activates the protein. Activation of PKR by this ss-
dsRNA suggests that the tails, by means not yet understood, contribute to PKR 
activation.  
 The Cole lab is working to define where PKR binds to ss-dsRNAs as well as 
determining their mechanism of PKR activation. Our studies are based on a model ss-
dsRNA : 15-15-15. The nomenclature for these RNAs is as follows: the first and last 
numbers represent the length of the 5’ and 3’ arms, respectively. The center number 
represents length of the double stranded stem. Modifications to this RNA have been 
accomplished and have involved symmetrically and asymmetrically shortening the 5’ 
and 3’ single-stranded-regions. It has been determined that the ss-regions of the 15-15-
10	  	  
15 RNA are required for PKR activation; deletion of either region abolishes the ability 
for PKR to become activated (Mayo and Cole, unpublished results). This observation 
suggests that the single-stranded regions are somehow interacting with PKR to induce 
activation.  
 In addition, PKR interactions with more complex inhibiting RNAs have been 
documented (29). One such RNA is Adenovirus Virus-Associated RNA I (VAI). Human 
cell infection by adenovirus results in the production of VAI which function to evade the 
immune response. VAI is a potent inhibitor of PKR that binds but fails to activate the 
protein (30). Inactivation of PKR by VAI is accomplished by tight binding of only a 
single monomer of PKR (31). The sequestering of a PKR monomer by VAI inhibits 
dimerization and therefore activation of PKR. Inactivation of PKR results in the 
continued replication of the virus within the host cell. It is believed that the secondary 
and tertiary structural features of VAI contribute to the high affinity binding of PKR to 
VAI. 
 It remains unclear as to how the structural features of inhibitory RNAs, such as 
VAI, and activating RNAs, such as ss-dsRNAs, contribute to either inhibition or 
activation of PKR (Figure 4). A method for determining the localized binding of PKR to 
RNA ligands is necessary in order to reveal how the binding of PKR to specific RNA 
structural features result in either the activation or inhibition of PKR.  
 
Developing a Crosslinking Construct of PKR 
 
Motivation 
 
 The approach taken here to determine the binding of PKR on structurally complex 
RNAs is to create a functional crosslinking construct of PKR. The construct would 
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ideally covalently bind to RNAs of interest in vitro upon UV irradiation. Successful 
development of these constructs would be useful to map the RNA structural regions 
PKR binds on activating or inactivating RNAs, such as ss-dsRNAs and VAI, respectively.   
 
A Method for Creating Crosslinking Constructs of PKR 
 Many techniques for identifying and characterizing protein-nucleic acid 
interactions have been described. One such technique requires the incorporation of an 
unnatural amino acid with photo-crosslinking capabilities into the protein of interest 
(32). 
 Photo-crosslinkers have been used extensively as probes to identify and map 
interactions between proteins and DNA or RNA molecules. Proteins of interest with 
incorporated photo-crosslinkers enable the protein to selectively form covalent 
complexes with their cognate DNA or RNA binding site upon UV irradiation. The 
crosslinking occurs upon sample exposure to UV light, whereby a reactive radical forms 
and in turn creates a covalent bond to proximal atoms.  The benefit of this approach is 
that it is possible to gain insight into the interaction interface between the biological 
macromolecules because it is possible to control the placement of the crosslinker.  
 The unnatural amino acid chosen for site-specific incorporation into PKR at 
dsRBM1 for this study was p-azido-L-phenylalanine (pAzF) (Figure 5). This unnatural 
amino acid was chosen because of the reactive chemistry of the azide functional group 
upon UV exposure. Upon UV radiation, the three doubly bonded nitrogens of the azide 
group participate in a reaction where a reactive radical is formed thereby rapidly 
inducing a covalent interaction with adjacent atoms. In addition, pAzF was the chosen 
unnatural amino acid because it is cost-effective.   
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Expanding the Cell’s Biosynthetic Machinery 
 In order to successfully incorporate the unnatural amino acid, it was necessary to 
add new components of the protein biosynthetic machinery into the Escherichia coli (E. 
coli) expression system used here. A method for incorporating unnatural amino acids 
into E. coli and Saccharomyces cerevisiae (S. cerevisiae) has been developed and was 
employed here (33). 
 To site-specifically incorporate the unnatural amino acid into PKR, a single codon 
that corresponds to the candidate amino acid residue for pAzF substitution was mutated 
to the amber stop codon TAG.   This was a critical step in the development of the 
constructs, as the codon coding for the unnatural amino acid must not code for any of 
the other endogenous amino acids. The TAG amber stop codon was used since it is the 
least used among the three stop codons in E. coli and because it has been shown to 
rarely terminate the synthesis of critical proteins.    
 As pAzF is not found normally within cells, it was necessary to introduce an 
orthogonal tRNA-aminoacyl-tRNA synthetase pair that could specifically incorporate 
pAzF into PKR in response to the TAG stop codon. Here, the orthogonal tRNA–
synthetase pair used was derived from a tyrosyl-tRNA synthetase pair from the 
archaeon Methanococcus jannaschii (34). Archaeal tRNAs have distinct aminoacyl-
tRNA synthetase recognition elements relative to E. coli, and therefore do not cross-
react with the endogenous synthetases of E. coli, this offers an advantage to using the 
pair in E. coli. The tyrosyl-tRNA synthetase pair is expressed at high levels and in a 
functional form in E. coli. The pair has consequently been used to incorporate a growing 
number of unnatural amino acids into proteins in E. coli (35). pAzF has been 
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successfully incorporated into other proteins and was shown to be efficiently translated 
by the amber suppressor tRNA in vivo and in vitro (36).  
 
Design of PKR Constructs 
 Each construct had the single pAzF incorporated within dsRBM1 of PKR. dsRBM1 
was selected for mutational analysis to test the potential of the method to map PKR’s 
localized binding on dsRNAs. The development of the constructs here is a pilot project 
to design and create other functional crosslinking constructs of PKR in different regions. 
These other regions on PKR include dsRBM2 and the kinase domain. These efforts are 
being made in order to determine where PKR is binding on certain structural features 
that in turn either activate or inactivate the protein.  
 In order to determine the amino acid residues on dsRBM1 that would be 
appropriate for pAzF incorporation, we aligned the dsRBD sequences of PKR, 
Drosophila Staufen protein, Xenopus laevis RNA-binding protein A-2 (Xlrbpa-2), E. 
coli RNAs III, and human TAR-RNA binding protein. The alignment was performed to 
determine which residues were highly conserved. The residues that were conserved 
among the five proteins were then eliminated from the pool of candidate amino acids 
because their conservation across proteins from different species suggests them to be of 
structural or functional importance.  
 Subsequently, the crystal structure of Xlrbpa-2 complexed with dsRNA was used as 
a basis for selecting target PKR residues because there is no structure of the PKR dsRBD 
bound to dsRNA (Figure 6) (37). The NMR structure of PKR dsRBD was overlayed with 
the crystal structure of Xlrbpa-2 using PYMOL. Residues were selected on the basis of 
their proximity to the RNA and on their sequence homology (Figure 7). 
14	  	  
 The structural homology between the dsRBD of Xlrbpa and the dsRBD of PKR 
readily allowed determination of candidate amino acid targets. The amino acid residues 
selected for substitution were F9, F43, D38, R39, N65, and E29 on PKR. Of these, we 
successfully substituted pAzF in place of F9, F43, E29, and D38. These constructs are 
designated F9pAzF, F43pAzF, E29pAzF, and D38pAzF respectively.  
 
 
Materials and Methods 
 
Plasmid selection  
  
The PKR gene and the lambda phosphatase gene were inserted into the pET-11a 
plasmid used here. In this modified pET-11a plasmid, the lambda phosphatase gene is 
downstream the PKR gene which is under the T7 promoter. Site-directed mutagenesis 
was performed on this modified plasmid to create PKR construct plasmids containing 
the site-specifically incorporated TAG amber stop codon. The pEVOL plasmid, which 
contained the M. jannaschii orthogonal tRNA-aminoacyl tRNA synthetase pair gene 
was used to transform the E. coli expression system used here along with the modified 
pET-11a PKR construct plasmid.  
 
Site-directed Mutagenesis 
The forward and reverse primers used for the site directed mutagenesis were 
ordered from IDT and each contained the TAG mutation at the sequence corresponding 
to a candidate amino acid (Figure 8). In each 50 µL PCR reaction mixture, primers were 
at a concentration of 0.2 µM with the template at a concentration of 10.4 ng/µL. Site-
directed mutagenesis was carried out under the following conditions using the Phusion 
HF polymerase purchased from New England BioLabs: 
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1. 95°C for 2 min 
2. 95°C for 30 sec 
3. 62°C for 30 sec 
4. 72°C for 4 min 
5. Go To step 2, 30-times 
6. 72°C for 5 min 
7. 4°C Hold 
 
Following the PCR reaction, 1 µL of DpnI (20,000units/mL) was added to each 50 µL 
PCR reaction and incubated for one hour at 47°C prior to transforming cells with the 
desired mutated plasmid.  
 
 Arctic Express Competent Cells from Agilent Technologies was the chosen cell 
line for transformation for antibiotic resistance screening purposes. 100 µL of Arctic 
Express Cells were thawed on ice and mixed gently for five minutes. The cells were then 
transformed with the mutated pET-11a and pEVOL plasmid. Both the pEVOL and pET-
11a plasmid (25ng/µL) were added to the cell mixture to a final concentration of 
50ng/µL. The cells were subsequently incubated on ice for 30 minutes and then heat 
pulsed in a 42°C water bath for 20 seconds. Next, the cells were transferred to an ice 
bucket for a 2-minute incubation period. 900 µL of warm SOC media was added to the 
transformation reaction and the sample was then incubated at 37°C for 1 hour with 
shaking at 250 rpm. 100 µL of transformed cells were grown on LB agar plates 
containing carbenicillin and chloramphenicol to select for the pET-11a and pEVOL 
plasmid, respectively. The plates were then incubated for 18 hours at 37°C. 
 
Large-Scale Protein Expression 
 
 To prepare for large-scale protein expression, 10 mL aliquots of sterile LB 
containing chloramphenicol and carbenicillin were inoculated with a single colony from 
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the growth plate. The 10 mL cultures were incubated at 37°C with shaking at 250 rpm 
for 18 hours. Following growth, two 2 L flasks containing LB Broth without antibiotics 
were each inoculated with 10 mL of overnight culture and incubated at 37°C. Cell growth 
was monitored by collecting 1 mL of cell culture sample and measuring the absorbance 
of the sample at 600 nm. When the absorbance of the cell sample reached 
approximately 0.2, 500 µL of Arabinose (20%) was added along with 1 mL of pAzF 
solution (0.5 M in 1 M NaOH). Arabinose was added in order to induce expression of the 
tRNA-aminoacyl synthetase pair gene. Once the absorbance of the cell sample reached 
approximately 1, the cell cultures were cold-shocked for 15 minutes at 4°C and 1 mL of 
pre-induction samples were collected. After cold shocking, the cultures were induced 
with 500 µL of 1 M IPTG. The cell cultures were then allowed to incubate at 37°C until 
the samples reached an absorbance close to 2. 1 mL post-induction samples were 
collected for SDS-PAGE analysis. The 500 mL cultures were then spun down at 8,500 
rpm for 10 minutes and the cell pellet was saved for protein purification at -80°C.      
Prior to thawing the post-induction cell pellets, 400 µL of Sigma Protease 
Inhibitor Cocktail per liter of cell culture was added to the pellet. After thawing, the 
pellet was suspended in 8.3 mL of Buffer A. 
Buffer A: 20 mM HEPES, pH 7.5 
50 mM NaCl 
0.1 mM EDTA 
10% Glycerol 
 
Cell lysis was accomplished by sonication using the Fisher Scientific Sonic 
Dismembrator Model 100 sonication machine. The cell sample was sonicated for 40 
seconds six times at the 8th setting on ice. In between each 40-second interval the 
sonicator was turned off. Following sonication, the sample was centrifuged at 22000 g 
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for 20 minutes and the supernatant was saved. The pellet was then suspended in 5 mL 
Buffer A and sonicated again as above. The cell sample was then re-centrifuged for 
22000 g for 20 minutes and the supernatant was collected. Supernatant samples from 
the first and second centrifugation were then pooled and centrifuged one last time.        
 
 
Protein Purification 
 
 For each 1 L prep, a single 5 mL HiTrap Heparin HP column was used. The 
column was first washed with Buffer A prior to run for a volume of 50mL at a flow rate 
of 2.5 mL/min. Subsequently, to remove any excess material on the column that was 
flown through it previously, the column was washed with 13% of Buffer B until the OD 
was done to a baseline flow rate.   
Buffer B: 20 mM Hepes, pH 7.5 
1.2 M NaCl 
0.1 mM EDTA 
10% Glycerol 
 
 The supernatant acquired from the cell-lysis purification step was loaded  
 
onto the Heparin column at 2.5 mL/min. Then, Buffer B was used to elute the protein 
from the heparin column. 20% of Buffer B was initially used to elute the protein. 
Increasing the percentage of Buffer B used by 5% increments until the percent of Buffer 
B used to elute the protein was 80% subsequently eluted the rest of the protein sample. 
The PKR construct containing fractions were then stored at 4°C overnight. Due to time 
constraints, no further purification of the constructs was performed.       
 
Prior to using each protein sample in a crosslinking reaction, the  
absorbance of each sample at 280 nm was determined. As each protein sample was not 
entirely pure, five absorbance readings at 280 nm were taken and the average of the five 
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absorbances was calculated. The mean absorbance value was used to determine the 
approximate concentration of the PKR construct in the heterogeneous protein sample. 
The Beer-lambert law was employed in calculating the concentration of PKR construct 
using the extinction coefficient of PKR ε=43341.9 M-1cm-1.  
 
Labeling with a Fluorescent Fluorophore 
 
 In order to verify the incorporation of pAzF in each construct, the Heparin 
purified protein samples were reacted via click chemistry with an Alexafluor® 488- 
conjugate containing a strained alkyne reactive group.  250 µL of each protein sample 
was incubated with 2.0 µL of the fluorophore conjugate (10 mM) for one hour. 
Following the one-hour incubation period, the protein sample was buffer exchanged 
into AU75 buffer.  
AU75 Buffer: 20 mM Hepes, pH 7.5 
75 mM NaCl 
0.1 mM EDTA 
 
 Prior to the exchange, 2.5 mL of 1x P6 Biogel beads were added to a 15 mL falcon 
tube and centrifuged for four minutes at 1000 rpm to separate the beads from the TE 
Buffer. The supernatant was then removed and 5 mL of AU75 Buffer was added to the 
tube, mixed, and centrifuged for 4 minutes at 1000 rpm. This was repeated three more 
times and following each centrifugation, the supernatant was removed. For the fifth 
centrifugation step, a Pierce Centrifuge column was placed into the 15 mL falcon tube 
and the AU75 buffer-bead mix was transferred to the column and centrifuged again. The 
flow through was then disposed. After the last centrifugation with AU75, a new 15 mL 
collection tube was used and the 250 µL labeled sample was loaded into the column 
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containing the beads and centrifuged at 1000rpm for four minutes. The buffer-exchange 
protein sample was then collected for analysis     
The absorbance of the protein sample at 488 nm was then determined using the 
Thermo Scientific NanoDrop 2000. Successful incorporation of the unnatural amino 
acid is indicated by an absorbance peak at 488 nm in the spectrum due to the Alexa 
Fluor absorbance. 
 
Crosslinking  
 
 For the crosslinking studies, the 115 VAC UV lamp from Cole Palmer was used to 
crosslink samples at 254 nm, 302 nm, or 365 nm. A 96-well plate was used to hold the 
samples and the samples were placed on ice during the entire crosslinking procedure. 
The UV lamp was held approximately 2 cm from the 96-well plate.  
 Each purified PKR construct was crosslinked in the presence of a 45 bp duplex 
RNA or a 15-15-15 RNA at wavelengths of 254 nm, 302 nm, or 365 nm. Wild type PKR 
(WT PKR) was also crosslinked at 254, 302, and 365 nm with either type of RNA as a 
control. In each 20 µL crosslinking reaction, the final concentration of RNA and protein 
was 1 µM and 4 µM respectively. Au75 was the buffer used in each reaction and enough 
of the buffer was added to reach a final volume of 20 µL. 20 µL of UV exposed samples 
were collected following exposure over the course of 1, 2, 5, 10, and 30 minute(s). 
In addition, both WT PKR and the PKR constructs were exposed to UV light at 
254 nm, 302 nm, or 365 nm in the absence of RNA. Samples were collected at the same 
time points as mentioned above. Lastly, samples at the same six time points were 
collected for WT PKR and the PKR constructs incubated with either RNA type that was 
not exposed to UV light.  
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45bp duplex RNAs purchased from Dharmacon were prepared by annealing the 
complementary top (88 µM) and bottom strands (84 µM). For the annealing procedure, 
the RNAs were incubated together at equimolar concentrations of 20 µM and heated in 
a heat block at 90°C for five minutes. Following heating, the samples were allowed to 
cool in the heat block on a bench top until the temperature of the samples reached room 
temperature. The annealed samples were then stored in 7 µL aliquots at -80°C.  
 The 15-15-15 RNA samples were prepared by diluting the stock sample (197 µM) 
to 2 µM in AU75 buffer. The RNA sample was than annealed after diluting by heating 
the sample to 90°C for five minutes and then by plunging it into ice for ten minutes. 100 
µL aliquots were then stored at -80°C. 
   
 
Gel Electrophoresis 
 
 12% Resolving and 4% stacking SDS-PAGE gels for this experiment were 
prepared according to the Bio-Rad SDS-PAGE preparation protocol. In all cases, the 
running buffer used was 1X Tris-glycine. The gels were run at 200 V and 500 mA for 50 
minutes. In all gels, 5x gel loading buffer was added to gel samples to 20% (v/v). BME 
was not added to the 5X loading gel buffer prior to loading to avoid reducing the azide 
group on the unnatural amino acid.  The gel-loading buffer was prepared as shown 
below. 
5X Gel Loading Buffer: 312.5 mM Tris-HCl 
10% SDS 
50% Glycerol 
0.005% Bromophenol Blue 
5 mM EDTA   
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Results 
 
 The sequencing results for four out of the six construct plasmids showed 
successful incorporation of the TAG codon in the appropriate location (data not shown). 
Problems with the PCR did not allow for successful substitution of the TAG amber stop 
codon at the appropriate positions to make N65pAzF and R39pAzF construct plasmids.  
As indicated by SDS-PAGE, all post-induction cell lysate samples showed no 
significant amounts of PKR construct present where both inducers were added (Figure 
9-10). However, the presence of lambda phosphatase (λ PP) is suggested in the cell 
lysate samples containing IPTG. λ PP is approximately 25kDa in size and prominent 
bands appear between the 26kDa and 19kDa markers in the cell lysates containing IPTG 
(Figure 9-10). The presence of this protein was not verified by western blotting. λ PP 
kept the PKR constructs in their unphosphorylated form.    
Despite the minimal presence of PKR constructs in the post-induction samples, 
large-scale protein expression was pursued followed by purification by Heparin column 
to determine if it was the case that really small amounts of each PKR construct were 
being produced by the E. coli cells used here rather than none. 
As indicated by SDS-PAGE of the fractions, PKR construct was present. Bands 
close to the WT PKR band are found across all construct samples purified by Heparin 
column (Figure 11-14). The fractions selected for pooling were typically fractions 24, 25, 
or 26 up to fraction 32 for the F43pAzF, D38pAzF, and E29pAzF constructs purified 
(Figure 11-13). However, for the F9pAzF construct, fractions 36—44 were pooled (Figure 
14). The pooling strategy was such that only fractions containing minimal amounts of 
contaminant protein were pooled. Of great importance was to eliminate as much of the 
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protein that appears immediately below the PKR band as shown by SDS-PAGE. Further 
purification was not accomplished due to time constraints.  
Following the labeling of each PKR construct with Alexa488 and buffer exchange 
into AU75, the absorption spectrum of each partially purified protein sample was 
recorded. It was assumed that the fluorescently labeled heterogeneous protein sample 
contained mostly labeled PKR construct and minimal amounts of labeled endogenous E. 
coli protein. Additionally, it was assumed that only a negligible amount of endogenous 
E. coli protein had incorporated pAzF because the amber stop codon is rarely used in E. 
coli.  As indicated by the spectra, the fluorophore was successfully incorporated into the 
following constructs: F43pAzF, D38pAzF, and E29pAzF (Figure 15-17). The fluorophore 
was not successfully incorporated into F9pAzF and the spectrum is not shown here. WT 
PKR was labeled with the flurophore as a control (Figure 18).  As can be seen in the 
absorption spectra for each successfully labeled construct, an absorbance peak is 
observed at 488nm in addition to absorbance peaks at 230nm and 280nm. An 
absorbance peak at 488nm suggests successful pAzF incorporation because the 
fluorophore in coordination with the azide group on pAzF absorbs light at this 
wavelength. For WT PKR, the peak at 488nm is not observed since it does not contain 
the unnatural amino acid.  
Crosslinking at 254nm of WT PKR in the absence of RNA resulted in significant 
cross-linked product formation over a 30-minute time course (Data not shown). Cross-
linked product formation was also observed in the crosslinking reaction of WT PKR in 
the presence of a 40bp RNA or a 15-15-15 RNA at 254nm over time (Data not shown). 
Crosslinking of WT PKR at 302nm in the absence of RNA or the presence of either a 
45bp RNA or a 15-15-15 RNA also resulted in the formation of cross-linked products 
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near the top of the gel except in smaller amounts compared to the crosslinking reactions 
done at 254nm (Figure 19).  
Crosslinking of the F43pAzF mutant at a wavelength of 254nm also resulted in 
crosslinked product formation in the absence of RNA and in the presence of either 45bp 
RNA or a 10-15-15 RNA (Figure 20). Subsequent crosslinking experiments were not 
performed with this mutant due to limited availability. Crosslinked products also 
formed in the absence and presence of RNA with the E29pAzF construct upon 302nm 
UV light exposure (Figure 21). Crosslinking at 254nm with this construct was not 
performed because protein-protein products are inevitable under these conditions.  
Since protein-protein and protein-RNA crosslinked products were inevitably 
forming upon sample exposure to 254nm or 302nm wavelengths of light, subsequent 
crosslinking reactions with the remaining PKR constructs were performed at a 
wavelength of light of 365nm. 
As revealed by SDS-PAGE, crosslinking of WT PKR in the absence or presence of 
RNA at 365nm resulted in no crosslinked product formation over a 30-minute time 
course (Figure 22). This was a desirable outcome for the project because it eliminated 
non-specific crosslinking.  
SDS-PAGE shows no crosslinked product formed as a result of crosslinking the 
E29pAzF or D38pAzF construct in the absence of RNA at 365nm over time (Figure 23—
24). Crosslinking of D38pAzF to a 15-15-15 ss-dsRNA or to a 45bp dsRNA over time 
shows no convincing crosslinked product formation over time (Figure 25). In addition, 
no convincing crosslinked product is formed as a result of E29pAzF crosslinking with a 
45bp dsRNA or to a 15-15-15 ss-dsRNA under the same conditions (Figure 26). In either 
case, very minor banding occurs at the top of the gel at the 30-minute time point but it is 
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not significant. This banding could be background material and not crosslinked product. 
Western blotting could have been performed to verify that the bands are crosslinked 
products that contained the constructs and not of any other endogenous E. coli proteins 
as well. 
 
Discussion 
 
Throughout the course of this project, several challenges were faced. The first was 
obtaining adequate levels of each PKR construct. PKR construct induction tests revealed 
no observable amounts of PKR construct in the cell lysate samples induced with IPTG 
and arabinose. Large-scale protein expression was still pursued followed by purification 
by Heparin column to determine if it was the case that the Arctic Express cell line was 
producing minimal amounts of the protein rather than none. SDS-PAGE of the fractions 
pooled for each construct purified by Heparin suggested the presence of the respective 
constructs. This suggested than that minimal amounts of PKR construct were being 
produced within the cells used here. Low levels of PKR construct were not considered to 
be due to low levels of pAzF in the growth media. The concentration of pAzF added here 
is considered appropriate and sufficient. Increasing the amount of pAzF in the growth 
media is not encouraged in the literature because increasing the concentration of pAzF 
in the media results in decreased cell growth rates (data not shown). For the purposes of 
obtaining sufficient PKR construct for the crosslinking reactions, more cells were grown.  
It remains a puzzle as to why PKR construct production was low in our E.coli 
cells. The high levels of λ PP in the cell lysate samples containing IPTG indicate that 
IPTG was inducing expression of the PKR construct gene and the λ PP gene since the 
two protein coding genes are in sequence with one another and are both under the T7 
25	  	  
promoter. Presumably the PKR construct and λ PP coding mRNA transcript is being 
produced and high levels of λ PP are being translated and maintained in the cells but 
minimal levels of PKR construct are being produced. Low levels of PKR construct could 
be because incorporation of pAzF into the growing peptide chain is not efficient; that the 
tRNA is not very effective at recognizing the amber stop codon. Alternatively, the Arctic 
Express Cells are recognizing the amber stop codon and producing truncated PKR 
construct products and small amounts of full-length construct. pAzF incorporation at 
different positions within the Aha1 protein of S. cerevisiae also showed strong 
suppression of the amber stop codon for each variant (38). These explanations are just 
educated assumptions and by no means are sufficient alone to explain what is occurring 
intracellularly. Studies to determine the mechanisms responsible for low PKR construct 
production were not performed here. 
After large-scale protein expression, purification by Heparin column was 
achieved followed by labeling of each partially purified construct-containing sample. 
Labeling each PKR construct protein was key because it was necessary to verify that 
pAzF was successfully incorporated into the protein prior to using it in crosslinking 
studies. While the absorption spectra of each partially purified PKR construct sample 
showed incorporation of the fluorophore, it does not suggest that only the PKR 
construct had pAzF incorporated into it. The probability exists that at least some E. coli 
proteins contained pAzF if any other endogenous mRNA transcripts also contained the 
UAG amber stop codon. However, it was assumed here that a negligible amount of 
endogenous E. coli proteins contained pAzF because the amber stop codon UAG is 
rarely used in E. coli (39). Only 7% of the E. coli protein coding genome contains an 
amber stop codon. Had any of these endogenous E. coli proteins contributed to the 
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crosslinking observed in any of the crosslinking experiments performed here, their 
contribution was assumed to be negligible.  
After successful labeling, samples with either construct in the absence and 
presence of RNA were exposed to UV light of different wavelengths to induce 
crosslinking. Samples containing WT PKR with or without RNA were also exposed to 
different wavelengths of UV light. This was done to verify that crosslinking upon UV 
light exposure was specific to the constructs only in the presence of RNA.  
We found that inducing crosslinking with UV light at 365nm was appropriate for 
PKR construct-RNA binding studies. Wavelengths shorter than 365nm (254nm and 
302nm) were deemed inappropriate for PKR construct-RNA binding studies because 
they induced crosslinking in samples containing WT PKR or PKR construct in the 
absence and presence of RNA. The formation of cross-linked products with WT PKR 
was not expected because WT PKR does not contain the photoreactive unnatural amino 
acid pAzF.  Additionally, crosslinking was only expected to occur between constructs 
that contained pAzF in the presence of RNA. 
Recently it was shown that it is possible to induce covalent crosslinks in 
biologically relevant peptides upon short and medium UV wavelength irradiation. 
However, only peptides containing aromatic side chains generate crosslinked products 
upon exposure to UV light, demonstrating that the crosslinking reaction requires the 
presence of aromatic amino acids (40). The aromatic amino acids tryptophan, tyrosine, 
and phenylalanine absorb UV light and are highly susceptible to oxidation by one or 
more reactive oxygen species (ROS) generated following UV light exposure (41). Upon 
absorption of UV light, the aromatic side chains produce ROS such as OH or O2-•, 
which consequently react readily to generate covalent bonds with neighboring residues 
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or other molecules (42-44). Presumably, the aromatic side chains within WT PKR are 
mediating the crosslinking between the proteins to itself upon 254nm or 302nm UV 
light exposure. The same could be occurring between the constructs crosslinked here at 
short and medium wavelengths.  
In addition, UV induced protein-nucleic acid crosslinking has been well 
documented (45-47). In particular, extensive protein-nucleic acid crosslinking occurs 
following UV light exposure within the 220nm-290nm range.  Presumably the aromatic 
residues in the constructs and WT PKR are mediating the crosslinking of the protein(s) 
to RNA following short and medium wavelength exposure. Crosslinked products 
presumably do not form upon 365nm UV light wavelength exposure because this 
wavelength is outside the optimal electromagnetic absorption range of the aromatic 
residues (48). Non-crosslinking of WT PKR at 365nm was encouraging because it 
suggested crosslinking with the PKR constructs could be performed at this wavelength 
without having background non-specific (WT PKR) crosslinking occurring as well. 
Once crosslinking was determined to be appropriate at 365nm of light, 
crosslinking experiments were performed with two PKR constructs in the presence and 
absence of RNA. Crosslinking of the E29pAzF or D38pAzF construct in the absence of 
RNA resulted in no crosslinked product formation.  A qualitative analysis of the SDS-
PAGE results for E29pAzF or D38pAzF crosslinking to RNA suggest no significant or 
convincing amount of crosslinked product formed over time. The insignificant decrease 
in band intensity of each non-crosslinked PKR construct over time also supports this. 
By qualitative analysis alone, it is not readily discernible whether the minor 
banding appearing at the top of the gel at the 30-minute time point in the SDS-PAGE of 
the D38pAzF crosslinked sample with a 45bp dsRNA and the E29pAzF with either RNA 
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type is certainly protein-RNA crosslinked product. The banding may just be background 
material. Verification of the identity of the banding could have been performed by 
western blotting or with more sensitive methods. If indeed the crosslinked products 
formed contained either construct, further experiments could be performed to 
determine how to optimize the amount of crosslinked product formed. Verification 
would also be necessary to show that the crosslinked products predominantly contained 
the pAzF incorporated PKR constructs rather than any other pAzF incorporated 
endogenous E. coli protein(s). 
Perhaps crosslinking is occurring but at really low levels which SDS-PAGE cannot 
resolve. Crosslinked product formation could be supported by either the appearance of 
bands towards the top of the gel over time, or by the decrease in intensity of the 
uncrosslinked PKR construct band over time. The crosslinking experiments performed 
with E29pAzF or D38pAzF do not suggest either to be the case. Perhaps the decrease in 
the non-crosslinked band intensity is minimal and reflects the formation of crosslinked 
product at the top of the gel. However, we cannot be certain of this until studies to verify 
this have been performed.   
It was expected that had crosslinking occurred between any construct and RNA, 
PKR construct crosslinking would be more prominent with a 45bp dsRNA than to a 15-
15-15 ss-dsRNA. The reasoning behind this is because the binding event of the second 
PKR monomer on a 40bp dsRNA is 52.5nM [Kd2] in Au75 (49), whereas the binding 
event of the second PKR monomer on a 15-15-15 ss-dsRNA is 294nM in AU75 (Cole and 
Mayo unpublished results). It was assumed that the dissociation constant of two PKR 
monomers on a 45bp dsRNA is comparable to the 40bp dsRNA case although this has 
not been demonstrated. Presumably crosslinking would have more readily occurred 
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between more tightly bound PKR construct—RNA ligands assuming the incorporation 
of pAzF into PKR did not perturb PKR construct binding to RNA ligands or affinity for 
them.  
Autophosphorylation assays and binding assays were not performed here to 
verify that incorporation of pAzF did not significantly alter the protein’s activation or 
affinity for RNA. If pAzF did affect the structure of E29pAzF or D38pAzF, it could have 
affected its affinity for RNA and consequently this could have affected the crosslinking 
reaction. 
 
Future Directions 
Overall, the crosslinking studies performed here at 365nm of UV light with 
E29pAzF or D38pAzF are not sufficient to suggest the functionality of either construct 
as a potential tool for PKR-RNA mapping studies. In the future, very pure protein 
samples of any of the four constructs made here should be crosslinked to RNA to 
eliminate crosslinking of E. coli pAzF-incorporated proteins to RNA. Prior to this 
however, autophosphorylation and gel-shift assays should be performed to verify that 
pAzF incorporation did not affect PKR activation or binding to RNA. A comparative 
analysis of the crosslinked products that result from the crosslinking could yield insight 
into which construct is preferable for crosslinking studies. Presumably, the construct 
that yields the most crosslinked product would be the preferred one to use in PKR-RNA 
mapping studies.  
If crosslinking of either construct at 365nm results in similar results obtained 
here, the position of pAzF can be substituted to make new constructs. One reason a 
small amount of cross-linked product maybe forming is because the RNA backbone is 
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not readily accessible to the azide group in the construct. The azide group within the 
crosslinker must make close enough contact with the RNA backbone so that upon UV 
irradiation, covalent interaction of the azide group of pAzF to the RNA can readily 
occur. Crosslinked product yield has been shown to depend on the location of pAzF into 
the protein of interest (38). Perhaps the location of pAzF on some of the constructs 
made here is not ideal and is causing low crosslinked product yield. For future projects 
the crosslinker could be placed at other regions on PKR for optimization purposes.   
Alternatively, pAzF could be substituted with a different unnatural amino acid 
that is photoactivateable at long wavelengths. Crosslinking studies have been performed 
in the past using the unnatural amino acid p-benzoyl-phenylalanine (pBpa) (50). pBpa 
has been used extensively to characterize protein-protein interactions and protein-DNA 
interactions (51-53).  
The use of pBpa as the preferred photoreactive group for photoaffinity 
crosslinking experiments is because of the following. The benzophenone group in pBpa 
is chemically more stable than alternative photoreactive groups such as diazo esters, aryl 
azides, or diazarines (54). pBpa’s wavelength range of activation (350nm-360nm) 
causes no harmful effects to protein and it preferentially covalently binds to C-H atoms 
(55). Also and most importantly, unlike other photoreactive groups, the excitation of 
benzophenone to a ROS diradical triplet stage is reversible. Upon excitation with UV 
light, if there is no interacting partner available in close proximity, the benzophenone 
group undergoes many chemical cycles until a preferable geometry for covalent 
modification is achieved (56). This property, combined with an optimal lifetime of the 
excited state, results in efficient covalent modifications of macromolecules, usually with 
high site specificity. In addition, benzophenone groups react minimally with water. This 
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is unlike the case for aryl azides where if no interacting partner is available in close 
vicinity, the group reacts with water (57). For the purposes of this study, it is highly 
desirable to use a photocrosslinker that is able to covalently bind site-specifically and to 
relevant molecules. pBpa is potentially a better candidate for site-specific incorporation 
into PKR than pAzF is because the wavelength needed to activate the benzophenone 
group on pBpa is long enough to avoid background non-specific crosslinking. In the 
future, incorporation of pBpa into PKR could be tried to see if its properties in effect 
allow for greater site-specific crosslinked product to form. 
Alternatively, groups with unique chemistry such as a specific metal chelator 
could be attached to the azide group on pAzF within the PKR constructs already made 
here to identify the binding sites of dsRBM1 on RNA ligands by affinity cleavage. Upon 
interaction with RNA, the metal chelator within the protein would induce cleavage of 
the RNA at the interaction interface.  The affinity cleavage approach has been performed 
previously and led to the identification of binding sites for the individual dsRMBs on 
various RNA ligands including VAI (58). Similarly, the affinity cleavage approach could 
be employed here to characterize the binding sites of PKR to RNAs of the ss-dsRNA type 
and many others. 
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Figure 1. PKR is Involved in the Intracellular Innate Immune Response (59). 
PKR is one component in the innate immune response and is indicated here in red. The 
protein is induced by interferon in a latent state and is activated upon binding to dsRNA. 
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Figure 2. PKR Structures. 
PKR consists of an N-terminal dsRNA binding domain (dsRBD) and a C-terminal kinase 
domain connected by a ~90 residue linker. The dsRBD is comprised of two tandem dsRBMs 
both with a conserved αβββα fold. 
Figure 3. PKR Activation and Dimerization Model 
Upon binding to dsRNA, two PKR monomers dimerize on the duplex RNA and 
induce activation of the dimer by autophosphorylation at the kinase domain 
shown here in yellow 
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Figure 4. RNA Activator or Inhibitor of PKR 
PKR has been shown to bind and either become 
activated or inactivated by non-entirely duplex 
RNAs. An RNA activator and inhibitor of PKR such 
as stem-loop RNA and VAI are shown in green and 
red respectively. 
	  	  
Stem loop RNA 
Adenovirus  
VAI 
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Figure 5. The Unnatural Amino Acid: p-azido-l-
phenylalanine 
The azide region of the amino acid involved in the 
crosslinking reaction is denoted in orange. 
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Figure 6. Structure of PKR’s dsRBM1 and Xlrbpa-2 
Complexed with dsRNA   
There is an available solution crystal structure of PKR’s 
dsRBM1 and Xlrbpa complexed with dsRNA. Both are shown 
here in blue and black respectively.  
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Figure 7.  PKR’s dsRBM1 Overlaid with Xlrbpa Bound to dsRNA 
F43, F9, E29, D38, N65, and R39 are the candidate residues shown in 
green, pink, red, orange, purple, and light blue respectively. 
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F9pAzF  
Forward Primer—5’-TCTTTCAGCAGGTTAGTTCATGGAGGAACTTAATACATAC-3’ 
Reverse  Primer—5’-GTTCCTCCATGAACTAACCTGCTGAAAGATCACCAGCCAT-3’ 
 
E29pAzF  
Forward Primer—5’-ACTTAAATATCAATAGCTGCCTAATTCAGGACCTCCACATGATA-3’ 
Reverse  Primer—5’-CTGAATTAGGCAGCTATTGATATTTAAGTACTACTCCCTGCTTCT 
 
D38pAzF  
Forward Primer—5’-AGGACCTCCACATTAGAGGAGGTTTACATTTCAAGTT 
Reverse  Primer—3’- ATGTAAACCTCCTCTAATGTGGAGGTCCTGAATTAGGCAG 
 
F43pAzF  
Forward Primer—5’-TAGGAGGTTTACATAGCAAGTTATAATAGATGGAAGAGAA-3’ 
Reverse  Primer—5’-CTATTATAACTTGCCTAGTAAACCTCCTATCATGTGG 
 
N65pAzF 
Forward Primer—5’-AGGACCTCCACATTAGAGGAGGTTTACATTTCAAGTT 
Reverse  Primer—3’- ATGTAAACCTCCTCTAATGTGGAGGTCCTGAATTAGGCAG 
 
R39pAzF  
Forward Primer—5’-ACCTCCACATGATTAGAGGTTTACATTTCAAGTT-3’ 
Reverse  Primer—5’-GAAATGTAAACCTCTAATCATGTGGAGGTCCTGAATTAGG 
 
Figure 8. Primer Design 
Above are the sequences of the primers used in the site-directed mutagenesis for the 
creation of each PKR plasmid construct. 
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Figure 9. PKR Construct Induction I 
Shown above are the cell lysates of transformed Arctic Express cells containing their respective PKR construct. The 
cells were induced with IPTG (+) and Arabinose(+) to induce gene expression of the PKR construct and of the 
aminoacyl-tRNA synthetase pair respectively. 
  
Protein                       WT PKR                 F9pAzF                          D38pAzF                         E29pAzF                F43pAzF                   
IPTG                                              -         +        -         +        -             +         -         +          -        +       -     +      -      +      -         + 
Arabinose                                   +        +        -          -        +            +         -          -          +       +       -      -      +     +       -         - 
37 kDa 
26 kDa 
19 kDa 
48 kDa 
64 kDa 
82 kDa 
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Protein                       WT PKR       F9pAzF         D38pAzF        E29pAzF          F43pAzF       
IPTG                                                    -          +            -            +            -         +             -             + 
181 kDa 
115 kDa 
82 kDa 
64 kDa 
48 kDa 
37 kDa 
26 kDa 
19 kDa 
15 kDa 
Figure 10. PKR Construct Induction II 
Shown above are the cell lysates of transformed Arctic Express cells containing their 
respective PKR construct. The cells were induced with IPTG to induce gene expression of 
the PKR construct.  
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Figure 10. F43pAzF Heparin Column Gel Fractions   
     Fraction                  14          16        18          20        22         24        26         28        30         32         34          36                      
WT PKR 
Figure 11. F43pAzF Heparin Column Gel Fractions   
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Figure 12. D38pAzF Heparin Column Gel Fractions   
         
    Fraction                   7     10    13      17     19    21     23    25     27    29      31     34                       
WT PKR 
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Figure 13. E29pAzF Heparin Column Gel Fractions   
         
   Fraction                 12      14      16     18      20    22      24      26    28     30      32      34                       
WT PKR 
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Figure 14. F9pAzF Heparin Column Gel Fractions   
     
  Fraction              20      22     24       26       28     30      32     34     36      38    40     42     44    46          
WT PKR 
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Figure 15. Absorption Spectra of Labeled F43pAzF  
	   F43pAzF 
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Figure 16. Absorption Spectra of Labeled D38pAzF  
	  	  	   D38pAzF 
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Figure 17. Absorption Spectra of Labeled E29pAzF  
	   E29pAzF 
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Figure  18. Absorption Spectra of Unlabeled WT PKR 
	   WT PKR 
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Figure 19. Crosslinking of WT PKR with RNA at 302nm 
Protein                                      WT PKR                                         
RNA                                            No RNA 
Time (min.)           0       0       1        2       5      10    30 
Protein                                       WT PKR                                         
RNA                                         45bp dsRNA                                      
Time (min.)             0      1        2        5      10      30        
Protein                              WT PKR                                         
RNA                          15-15-15 ss-dsRNA                                      
Time (min.)      0      1       2     5    10    30        
Crosslinked Products 
Crosslinked Products 
Crosslinked Products 
WT PKR 
WT PKR 
WT PKR 
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Figure 20. Crosslinking of F43pAzF with RNA at 254nm 
Protein                           F43pAzF 
RNA                                 No RNA                                               
Time (min.) 0    0.5  1    2    5    10   30  60 
Protein                        F43pAzF 
RNA                          45bp dsRNA                                               
Time (min.)     0    0.5   1     2     5   10   30  
Protein                    F43pAzF 
RNA                   15-15-15 ss-dsRNA                                               
Time (min.)      0  0.5  1    2     5   10  30 60 
Crosslinked Products 
Crosslinked Products 
Crosslinked Products 
F43pAzF 
F43pAzF 
F43pAzF 
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   Figure 21. Crosslinking of E29pAzF with RNA at 302nm  
              Protein                               E29pAzF  
              RNA                                      No RNA 
              Minutes                0      1      2     5    10    30 
              Protein                             E29pAzF  
              RNA                         15-15-15 ss-dsRNA  
              Minutes                0      1      2     5    10    30 
Crosslinked Products 
              Protein                             E29pAzF                       
              RNA                               45bp dsRNA 
              Minutes                0      1      2     5    10    30 
Crosslinked Products 
Crosslinked Products 
E29pAzF 
E29pAzF 
E29pAzF 
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Figure 22. Crosslinking of WT PKR with RNA at 365nm 
Protein                                 WT PKR                                           
RNA                                       No RNA                                               
Time (min.)      0      0      1      2      5     10   30 
Protein                          WT PKR                                           
RNA                            45bp dsRNA                                               
Time (min.)    0       1      2      5    10    30 
Protein                              WT PKR                                           
RNA                          15-15-15 ss-dsRNA                                              
Time (min.)    0       1      2     5     10   30 
WT PKR 
WT PKR 
WT PKR 
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Figure 23. Crosslinking of E29pAzF in the 
Absence of RNA at 365nm 
   
E29pAzF 
Protein                                                 E29pAzF 
RNA                                                       No RNA 
Time (min.)          0             1            2           5           10          30  
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Figure 24. Crosslinking of D38pAzF in the 
Absence of RNA at 365nm 
   
Protein                                                D38pAzF 
RNA                                                       No RNA 
Time (min.)          0             1            2           5           10          30  
D38pAzF 
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Figure 25. Crosslinking of D38pAzF with RNA at 365nm 
   
Protein                                          D38pAzF                                   
RNA                                       15-15-15 ss-dsRNA                                                     
Time (min.)     0          1           2           5         10        30 
D38pAzF 
Protein                                           D38pAzF                                   
RNA                                             45bp dsRNA 
Time (min.)     0          1           2           5         10        30 
Crosslinked Products 
D38pAzF 
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Figure 26. Crosslinking of E29pAzF with RNA at 365nm 
   
Protein                                        E29pAzF                                   
RNA                                    15-15-15 ss-dsRNA                                                      
Time (min.)     0          1          2           5         10        30 
Crosslinked Products 
Protein                                      E29pAzF                                    
RNA                                        45bp dsRNA 
Time (min.)       0          1          2           5        10        30 
E29pAzF 
E29pAzF 
Crosslinked Products 
